Literature DB >> 9512168

Digoxin visual toxicity with therapeutic blood levels of digoxin.

M J Wolin1.   

Abstract

PURPOSE: To report two cases of digoxin-related visual disturbances associated with therapeutic blood levels of digoxin.
METHODS: Case reports. One patient reported shimmering lights in the field of vision of both eyes; the second patient had a corrected visual acuity of BE, 20/40 and generalized visual field depression in both eyes. Both patients experienced these symptoms while receiving digoxin.
RESULTS: Both patients had digoxin blood levels in the therapeutic range (1.7 and 1.0 ng/ml, respectively). Therapeutic levels are 0.5 to 2.0 ng/ml. After discontinuing digoxin, the first patient noted that the shimmering light symptoms resolved, and the second patient had improved visual acuity and visual fields.
CONCLUSIONS: Digoxin-related visual toxicity may be associated with therapeutic blood levels of digoxin. Recognition of this entity may avoid unnecessary testing and frustration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512168     DOI: 10.1016/s0002-9394(99)80161-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  [Bilateral reduction in vision in the morning, cardiological intensive care in the evening].

Authors:  T Menke; B Neppert
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

2.  Acquired colour vision deficiency in patients receiving digoxin maintenance therapy.

Authors:  J G Lawrenson; C Kelly; A L Lawrenson; J Birch
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

Review 3.  Spectrum of digoxin-induced ocular toxicity: a case report and literature review.

Authors:  Delphine Renard; Eve Rubli; Nathalie Voide; François-Xavier Borruat; Laura E Rothuizen
Journal:  BMC Res Notes       Date:  2015-08-23

4.  Colored floaters as a manifestation of digoxin toxicity.

Authors:  Lynn Shi; Linus D Sun; Jeffrey G Odel
Journal:  Am J Ophthalmol Case Rep       Date:  2018-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.